Celltrion gains EC approval for Avtozma, a RoActemra biosimilar for autoimmune diseases
Celltrion has received marketing authorization from the European Commission (EC) for Avtozma, a biosimilar to RoActemra (tocilizumab), expanding the company’s footprint in the immunology and ... Read More
Three biosimilars by Celltrion near EU approval following CHMP endorsement
Celltrion, a leading South Korean biopharmaceutical company, has received positive opinions from the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) ... Read More
Hasten Biopharmaceutical buys asset rights for 14 branded products from Celltrion
In a significant move, CBC Group, Asia's largest healthcare-dedicated asset management firm headquartered in Singapore, announced that its portfolio company, Hasten Biopharmaceutical, has successfully acquired ... Read More